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ARTICLE
A Mutation in CCDC50, a Gene Encoding an Effector of Epidermal
Growth Factor–Mediated Cell Signaling, Causes Progressive
Hearing Loss
Silvia Modamio-Høybjør, A´ngeles Mencı´a, Richard Goodyear, Ignacio del Castillo, Guy Richardson,
Felipe Moreno, and Miguel A´ngel Moreno-Pelayo
We previously mapped a novel autosomal dominant deafness locus, DFNA44, by studying a family with postlingual,
progressive, nonsyndromic hearing loss. We report here on the identiﬁcation of a mutation in CCDC50 as the cause of
hearing loss in the family. CCDC50 encodes Ymer, an effector of epidermal growth factor (EGF)–mediated cell signaling
that is ubiquitously expressed in different organs and has been suggested to inhibit down-regulation of the EGF receptor.
We have examined its expression pattern in mouse inner ear. Western blotting and cell transfection results indicate that
Ymer is a soluble, cytoplasmic protein, and immunostaining shows that Ymer is expressed in a complex spatiotemporal
pattern during inner ear development. In adult inner ear, the expression of Ymer is restricted to the pillar cells of the
cochlea, the stria vascularis, and the vestibular sensory epithelia, where it shows spatial overlap with the microtubule-
based cytoskeleton. In dividing cells, Ymer colocalizes withmicrotubules of themitotic apparatus.We suggest thatDFNA44
hearing loss may result from a time-dependent disorganization of the microtubule-based cytoskeleton in the pillar cells
and stria vascularis of the adult auditory system.
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Nonsyndromic hearing impairment, with hearing loss as
the sole clinical symptom, is a very common inherited
sensory disorder characterized by a vast genetic hetero-
geneity. Mutations in 1100 genes are predicted to be as-
sociated with this sensory deﬁcit in humans. At present,
99 loci for nonsyndromic hearing loss have been mapped,
and 42 of the responsible genes have been identiﬁed (He-
reditary Hearing Loss Home Page). The genes currently
identiﬁed encode a variety of proteins with different func-
tional roles in the auditory system.1–3 This repertoire will
presumably increase, given the complexity of the hearing
process and the large number of loci that have been
mapped but for which the responsible gene remains to be
identiﬁed.
Recently, we mapped a novel autosomal dominant deaf-
ness locus (DFNA44 [MIM 607453]) in a Spanish family
segregating progressive, postlingual, nonsyndromic sen-
sorineural hearing loss. The hearing loss in this family is
initially moderate and affects mainly low to mid frequen-
cies (125–2,000 Hz). Later, it progresses to involve all the
frequencies (a ﬂat audiometric proﬁle) and leads to a pro-
found hearing loss by the 6th decade. The onset of the
hearing loss occurs in the 1st decade of life (ages 6–10
years). No evidence of either vestibular dysfunction or tin-
nitus has been reported in the patients with DFNA44
hearing loss. In addition, CT rules out inner ear malfor-
mations as the cause of deafness.4 DFNA44 maps to chro-
mosome 3q28–29 within a 3-cM critical interval deﬁned
by markers D3S1314 and D3S2418. Sequence analysis
excluded CLDN16 (MIM 603959), FGF12 (MIM 601513),
and IL1RAP (MIM 602626) as genes responsible for
DFNA44 hearing loss. A novel gene, CCDC50, (UniGene
Hs.478682)5 was subsequently positioned in the interval.
This gene is ubiquitously expressed and encodes Ymer, a
protein recently identiﬁed as an effector of epidermal
growth factor (EGF)–mediated cell signaling.6,7 Another
UniGene for CCDC50 (Hs.592514) locates 3′ to Hs.478682
in the DFNA44 interval. Hs.592514 comprises 222 ESTs, 4
of which are cochlear (accession numbers AW020156.1,
H88039.1, H88255.1, and BI491203.1 [Morton Cochlear
EST Database]). It appears to constitute an alternate 3’
end for CCDC50, since a Gnomon program analysis
generates two hidden Markov models (hmm556752 and
hmm556986) that result in a more extended 3′ UTR region.
Consequently, we considered CCDC50 a putative candi-
date gene for DFNA44 hearing loss, given that it is ex-
pressed in cochlea. The human gene (UniGeneHs.478682)
is organized in 12 exons, and two alternative transcripts
have been identiﬁed thus far. The longer transcript (Gen-
Bank accession number NM_178335) contains a 1,449-nt
ORF encoding a protein of 482 aa, whereas a shorter var-
iant (GenBank accession number NM_174908) without
exon 6 encodes a protein of 305 aa and is predominant
in all the organs tested.5 Ymer does not show signiﬁcant
similarity with any described protein. The predicted ami-
no acid sequence for Ymer does not indicate the presence
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of transmembrane domains or a signal peptide, although
a coiled-coil domain is encoded by exons 3 and 4, and
two motifs interacting with ubiquitin (MIUs) are encoded
by exons 7 and 8 (MIU1) and by exons 8 and 9 (MIU2).8
Residues encoded by exon 5 undergo posttranslational
modiﬁcation. Lysine 129 is ubiquitinated, and tyrosines
145 and 146 are phosphorylated in response to EGF stim-
ulation. Ymer may inhibit down-regulation of the EGF
receptor (EGFR).9–11 At present, however, most aspects
of Ymer function are still poorly characterized.
We report here on the identiﬁcation of CCDC50 as the
gene responsible for DFNA44 hearing loss in the Spanish
family. We have also established the spatiotemporal ex-
pression pattern of Ymer in the mouse inner ear and have
investigated its subcellular localization. On the basis of
these results, we discuss the roles it may play during de-
velopment and functional maturation of the inner ear.
Material and Methods
The protocols of this study were approved by the institutional
review board of Hospital Ramo´n y Cajal (Madrid).
Mutation Screening of the Human CCDC50 Gene
Primers to PCR amplify all the exons and intron-exon boundaries
of the human CCDC50 gene were designed using Oligo 4.0 (Mo-
lecular Biology Insights). PCRs were performed in standard con-
ditions, as described elsewhere.12 PCR products were puriﬁedwith
the QIAquick PCR puriﬁcation kit (Qiagen) and were directly se-
quenced using the BigDye Terminator v3.1 Cycle Sequencing
Ready Reaction Kit in an ABI PRISM 3100 genetic analyzer (Ap-
plied Biosystems). To isolate the c.1394_1401dupCACGGCAT
mutation, the exon 11 amplimer obtained from patient III:1 (ﬁg.
1) was cloned into pUC19 (New England Biolabs), was trans-
formed into XL1-Blue competent cells, and was grown on Luria
Bertani plates with isopropyl-b-D-thiogalactopyranoside and X-
gal under ampicillin selection. Plasmid DNA obtained from sev-
eral white colonies was sequenced using pUC (-47) and pUC (-48)
universal primers. Mutant sequences contained a CACGGCAT 8-
bp tandem duplication. For the detection of the mutation in the
human population, we developed a size-based screening test in
which exon 11 is ampliﬁed with a pair of primers, one of which
is ﬂuorescently labeled. Allele size was obtained after capillary
electrophoresis in an ABI PRISM 3100 genetic analyzer (Applied
Biosystems), by analysis with the GeneScan program (Applied
Biosystems). The wild-type allele is 8 bp smaller than that of the
mutant.
RT-PCR Analysis for Transcript Variants of the Murine
Ccdc50 Gene
Total RNA was prepared from the mouse cochleae at embryonic
day (E) 18.5, postnatal day (P) 0, and P14 and from mouse lung,
brain, and liver at P58, and the contaminating genomic DNA was
eliminated using RNase-free DNase treatment. Approximately 1
mg of total RNA was reverse transcribed using SuperScriptase II
(Invitrogen) and oligo-dT primer. The sequences of primers used
to RT-PCR amplify the different transcripts of the mouse Ccdc50
gene are as follows: F1, 5′-CCATGGCCGACGTGAGTG-3′; F5, 5′-
TCTTTGTACCCATGTCATGAAGAAAA-3′; F6, 5′-ATTGCAAGAA-
GAAGAACTTTTGGAA-3′; F7, 5′-CGTGAGTGTAGATCAGTCCAA-
GTTG-3′; F8, 5′-CCATGTCATGAAGAAAATAATCTCTTG-3′; F10,
5′-CGCGGGGAGGTATTTCTGAG-3′; R1, 5′-CCAGAATGGCACA-
CAGAAGGAC-3′; R2, 5′-GCCGATCCCTTTTTGTTTGTATT-3′; R4,
5′-AGGCTGTTTGTTCTTTAATTTTGAG-3′; R8, 5′-CAAGAGATTA-
TTTTCTTCATGACATGG-3′; R9, 5′- CATTAGAAGTCGAGCAATT-
TCCAA-3′; and R14, 5′-CCATGGTGATGAGACTGCTTTTC-3′. Ta-
ble 1 summarizes the primer pairs used in the ampliﬁcation of
the different Ccdc50 transcript variants. Primary RT-PCRs were
performed in a thermocycler (Perkin-Elmer 9700) with the use of
0.75 U of FastStart Taq polymerase (Roche Applied Science) and
1:50 of the cDNA preparation in a ﬁnal volume of 15 ml; 40 cycles
(at 96C for 30 s, 58C for 30 s, and 72C for 1 min/kb) were used.
Secondary ampliﬁcations were done using nested primers (see
table 1) and 1.5 ml of a 1:100 dilution of the previous PCR (F1-
R4); 30 cycles (at 96C for 30 s, 63C for 15 s, and 72C for 30 s)
were used. Direct sequencing of PCR products was performed
following the standard procedure described above. RACE (rapid
ampliﬁcation of cDNA ends) analyses were performed on total
RNA from E17.5 whole-embryo mouse, with use of the Marathon
cDNA Ampliﬁcation kit (BD Biosciences-Clontech).
Northern Blot Analysis
Northern analysis was performed on a commercial blot (First-
Choice Mouse Blot I [Ambion]) containing mRNA from 10 dif-
ferent mouse tissues (heart, brain, liver, spleen, kidney, embryo,
lung, thymus, testes, and ovary), in accordance with the manu-
facturer’s instructions. Mouse Ccdc50 ORF cDNA (transcript 1)
was ampliﬁed with the F1-R1 primer pair, was cloned into pGEM-
5Zf() (Promega), and was linearized. Antisense transcripts were
generated using T7 polymerase (Strip-EZ RNA probe synthesis
[Ambion]) and were nonisotopically labeled (BrightStar Psoralen-
Biotin [Ambion]). The northern blot was hybridized overnight at
60C with the full-length antisense mouse Ccdc50 probe and was
washed at 58C three times at low stringency and two times at
high stringency. Nonisotopic detection was performed according
to the manufacturer’s directions (BrightStar Biodetect [Ambion]).
The blot was stripped and reprobed with antisense probe gen-
erated from pTRI-b-actin mouse control template (Ambion).
Antibodies and Immunoblot Analysis
Immune serum against two nonoverlapping synthetic peptides
based on the predicted sequence of the mouse Ymer protein lo-
cated in the N-terminal (peptide I, RIQEKKDEDIARLL) and C-
terminal (peptide II, NQHSTTWHLPKSES) regions of the protein
(see ﬁg. 2) were raised in rabbit (CovalAb). After three boosts of
immunization, the antiserum was afﬁnity puriﬁed. The speciﬁcity
of the polyclonal antibody was tested by immunoblotting of pro-
tein extracts prepared from the inner ear. In brief, cochleae from
P2 mice were homogenized and sequentially extracted with Tris-
buffered saline (TBS) (150 mM NaCl and 10 mM Tris-HCl [pH
7.4]), high-salt solution (1.0 M NaCl and 10 mM Tris-HCl [pH
7.4]), low-salt solution (10 mM Tris-HCl [pH 7.4]), and 1% non-
ionic detergent (1% Triton X-100 and 10 mM Tris-HCl [pH 7.4]).
High-speed centrifugation after each extraction was used to pro-
duce soluble supernatants from which the protein was precipi-
tated with trichloroacetic acid or acetone before gel electropho-
resis. The insoluble fraction remaining after centrifugation in TX-
100 solution was solubilized in SDS-PAGE sample buffer. Protein
Figure 1. Mutation analysis of CCDC50. A, Pedigree of the family with DFNA44 hearing loss. Square symbols represent males; circles
represent females. Black symbols represent hearing-impaired subjects; white symbols represent individuals with normal hearing. A
question mark inside a symbol indicates that the clinical status of the subject is unknown. Individuals V:4 and V:5 are DZ twins. B
and C, Fragment of CCDC50 exon 11 from patient III:1 showing the presence of two alleles, wild type and mutant, respectively, after
being cloned separately into the pUC19 vector. The eight nucleotides that are duplicated in the mutant allele are boxed. D, Alignment
of the C-terminal fragment of the deduced Ymer protein for both wild-type (wt) and mutant (mut) alleles. Arrow points to the site
where the frameshift takes place, and amino acids that are different in the two alleles are shown in bold. E, Diagnostic test for the
c.1394_1401dupCACGGCAT mutation, based on the separation of wild-type and mutant alleles with the use of an automated genetic
analyzer.
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Table 1. Primer Pairs Used in the
Ampliﬁcation of the Different Mouse Ccdc50
Transcript Variants
Transcript
Variant
and PCR
Primary PCR Nested PCR
Forward Reverse Forward Reverse
1:
1 F1 R4 … …
2:
1 F1 R4 F7 R9
2 F1 R4 F6 R2
3:
1 F1 R4 F7 R8
2 F1 R4 F5 R2
4:
1 F1 R4 F7 R8
2 F1 R4 F8 R9
3 F1 R4 F6 R2
5:
1 F1 R4 F7 R14
2 F1 R4 F10 R2
6:
1 F1 R4 F7 R14
2 F1 R4 F10 R9
3 F1 R4 F6 R2
7:
1 F1 R4 F7 R8
2 F1 R4 F8 R14
3 F1 R4 F10 R2
8:
1 F1 R4 F7 R8
2 F1 R4 F8 R14
3 F1 R4 F10 R9
4 F1 R4 F6 R2
samples were run under reducing conditions on 10% polyacryl-
amide gels and were transferred to a polyvinylidene ﬂuoride Hy-
bond-P membrane (Amersham Biosciences). Membranes were
blocked for 1 h with 3% semiskimmed milk in TBS Tween (TBST)
(150 mM NaCl, 10 mM Tris-HCl [pH 7.2], and 0.05% Tween 20)
and were incubated overnight with the primary antibody at 1:
400 dilution. After three washes with TBST, the membrane was
incubated with alkaline phosphatase–conjugated goat anti-rabbit
secondary antibody (DAKO) at 1:1,000 dilution, and the bound
antibodies were visualized with nitro-blue tetrazolium chloride/
5-bromo-4-chloro-3′ indolyl phosphate p-toluidine solution.
Transfections
NIH-3T3 and Hela cells were grown in Dulbecco’s modiﬁed Eagle
medium (Sigma) containing 10% fetal bovine serum, 1% gluta-
mine, and 1% penicillin/streptomycin under standard condi-
tions, were transiently transfected with JetPEI (Qbiogene), and
were processed for immunoﬂuorescence as reported elsewhere.13
For transfection purposes, mouse Ccdc50 transcripts 1 and 2 were
PCR ampliﬁed (forward primer, 5′-CCATGGCCGACGTGAGTG-3′;
reverse primer, 5′-CCAGAATGGCACACAGAAGGAC-3′) with the
use of mouse brain cDNA as a template and were cloned into the
dicistronic expression vector pIRES-hrGFP-1a (Stratagene), which
is driven by the cytomegalovirus promoter. Similarly, human
CCDC50 transcripts 1 and 2 were ampliﬁed with the forward
5′-CGGGCTCCGGATATTTGGTA-3′ and reverse 5′-TGAGTCCA-
TTTTCAAGGCAGATTC-3′ primers with the use of cDNA from
Epstein-Barr virus–transformed human B lymphocytes and
were cloned into the expression vector pIRES-hrGFP-1a (Strata-
gene), and the 8-bp duplication was introduced at exon 11 by
mutagenesis (Quick Change Site-Directed Mutagenesis Kit
[Stratagene]).
Immunohistochemistry
Mouse inner ears were dissected and ﬁxed in 3.7% formaldehyde
in 0.1 M sodium phosphate buffer (pH 7.4). Tissues obtained from
P5 mice onwards were decalciﬁed with 0.5 M EDTA (pH 8.0) for
5 d before sectioning. Inner ears were cryoprotected in 30% su-
crose in PBS, were embedded in 1% low-gelling agarose in 18%
sucrose in PBS, and the agar blocks were mounted for cryosec-
tioning onto microtome chucks with use of optimal cutting tem-
perature compound (Tissue Tek [Miles Scientiﬁc]). Sections were
cut in a cryotome at 30C.
For immunostaining, cryosections were blocked with 10%
horse serum in TBS containing 1 mM sodium azide for 1 h and
were incubated overnight with 1:100 dilution of the primary
antibody. After three TBS washes, the slides were incubated with
a 1:100 dilution of the ﬂuorescein isothiocyanate (FITC)–con-
jugated swine anti-rabbit secondary antibody (DAKO) for 1 h.
Sections were mounted in Vectashield H-1000 (Vector Labora-
tories). Staining speciﬁcity was conﬁrmed by substituting the
primary antibody with nonimmune rabbit immunoglobulin G
(IgG) at the same concentration or by preabsorbing antibodies
with the two peptide antigens. Preimmune sera from the rabbit
used to generate the polyclonal anti-Ymer antibody was also
used to check speciﬁcity. Tissue-section slides were visualized
in an Axioplan 2 ﬂuorescence microscope (Carl Zeiss), and the
images were captured with a Spot-Junior Camera (Diagnostic
Instruments).
For colocalization experiments, the following primary anti-
bodies were used: mouse monoclonal antibodies to a-tubulin (A-
11126 [Molecular Probes] and TU-16 [Abcam]), acetylated a-tub-
ulin (clone 6–11B-1 [Sigma]), polyglutamylated tubulin (T9822
[Sigma]), and b-tubulin I and II (clone JDR.3B8 [Sigma]). Primary
antibodies were detected with Alexa Fluor 594-conjugated goat
anti-rabbit IgG (HL) (Molecular Probes) and FITC-conjugated
goat anti-mouse F(ab′)2 IgG fragment (Sigma). Actin was detected
with rhodamine or Alexa-Fluor 350–conjugated phalloidin. For
colocalization studies, whole-mount and single-cell preparations
were analyzed on a Zeiss LSM510 laser scanning confocal
microscope.
Results
Identiﬁcation of the Mutation in CCDC50 Causing
DFNA44 Hearing Loss
Sequence analysis of all exons and ﬂanking intronic se-
quences of CCDC50 in the affected subject III:1 (ﬁg.
1A) revealed eight sequence variations (table 2). Seven
of these changes, located in exons 3, 6, 7, and 10, includ-
ed four silent changes and three nonsynonymous amino
acid substitutions that, with the exception of the syn-
onymous change at exon 3, corresponded to previous-
ly reported nonpathogenic SNPs. The remaining change
corresponded to a heterozygous mutation in exon 11
(c.1394_1401dupCACGGCAT, with respect to the longer
transcript [GenBank accession number NM_178335]). This
Figure 2. Analysis of Ccdc50 transcripts in the mouse inner ear. A, Schematic drawing of human (Hs) and mouse (Mm) Ccdc50 genomic
organization. Exons are represented by rectangles. The ORF is depicted in white, and the UTRs are dotted. The asterisk marks the site
where the mutation was found in the family with DFNA44 hearing loss. A diagram of the Ymer protein (striped) includes the position
of the two MIU domains and the peptides in the N- and C-terminal regions (gray bars) used for generating the polyclonal antibody.
Below, the eight Ccdc50 transcript variants detected in mouse inner ear cDNA are shown. Primers used to amplify each variant are
represented by arrows (see the “Materials and Methods” section). Primers F6 and R9 were designed to anneal with exons 7 and 9 (only
the three most 3′ bases of each one are capable of annealing with exon 9 or 7, respectively), and thus they were used to amplify
transcripts without exon 8. Primers F5, F8, and R8 were designed to anneal with exon 3b, and they were used to amplify transcripts
that contain this exon. Primers F10 and R14 are speciﬁc to exon 6. B and C, Sequences of mouse Ccdc50 exon 3b and exon 6, respectively.
Intronic sequences are in lowercase letters. D, ClustalW alignment between human (Hs) CCDC50 intron 3 and mouse (Mm) Ccdc50 exon
3b.
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Table 2. Sequence Variations Found in the ORF of the Human CCDC50
Gene of Patient III:1
Exon and
Sequence Variationa State
Protein Level
(Deduced)
dbSNP
Identiﬁcation
Number
3:
c.228CrT Heterozygous p.Arg76Arg Not described
6:
c.651TrC Homozygous p.His217His rs2028572
c.678ArG Heterozygous p.Lys226Lys rs2028573
c.773TrA Homozygous p.Ile258Asn rs2028574
c.908ArG Homozygous p.Lys303Arg rs4677728
7:
c.995TrC Homozygous p.Met332Thr rs293813
10:
c.1269CrA Homozygous p.Ser423Ser rs364519
11:
c.1394_1401dup Heterozygous p.Phe468HisfsX37 …
NOTE.—All variations, except c.678ArG (exon 6) and c.1394_1401dup (exon 11), were
also present in the individual with normal hearing, III:8, who did not inherit the disease
chromosome. The pathogenic mutation is displayed in bold.
a Changes refer to the cDNA of the long isoform (RefSeq number NM_178335), position
1 corresponding to the A of the ATG initiation codon.
8-bp tandem duplication leads to a frameshift that replaces
the last 15 aa of the protein by a novel 36-aa sequence
(p.Phe468HisfsX37) (ﬁg. 1B–1D). We took advantage of the
size difference between the wild-type and mutant alleles to
design a screening test to detect this mutation (see ﬁg. 1E
and the “Material and Methods” section). This test showed
that the mutation segregatedwith the hearing impairment
in the family. In addition, it was not present in 100 un-
related Spanish individuals with normal hearing. These
ﬁndings indicate that c.1394_1401dupCACGGCAT is the
pathogenic mutation responsible for DFNA44 hearing loss
in the family. We screened for this mutation in probands
from 280 unrelated Spanish families displaying nonsyn-
dromic sensorineural hearing loss. Of these patients, 135
belonged to families segregating autosomal dominant
hearing impairment, and the remainder belonged to fam-
ilies in which the pattern of inheritance could not be de-
ﬁned unambiguously. The mutation was not detected in
any of these probands.
Identiﬁcation of Ccdc50 Transcripts in the Mouse Inner Ear
The orthologous mouse Ccdc50 gene (UniGene
Mm.258985) is also predicted to encode two isoforms.
Transcript 1 (GenBank accession number NM_026202.2)5
lacks exon 6 and corresponds to the shorter human var-
iant. It is expressed in several tissues including the organ
of Corti (GenBank accession number BQ567072.1) and is
predicted to encode a protein of 305 aa. Transcript 2
(GenBank accession number NM_001025615.1), gener-
ated by exon 8 skipping, is expressed in the testis of the
adult mouse (GenBank accession number AK016827.1)
and is predicted to encode a protein of 290 aa (ﬁg. 2A).
Ccdc50 is widely expressed in most tissues tested, but there
is little information available concerning the different
transcripts that are present in these tissues and their ex-
pression at the different stages of mouse inner ear devel-
opment. We therefore performed RT-PCR analysis on
mRNA from the mouse cochlea at E18.5, P0, and P14. This
analysis detected the presence of transcripts 1 and 2 at all
three developmental stages (ﬁg. 3A and 3B). In addition,
we used 5′-RACE-PCR to investigate the presence of pu-
tative novel exons upstream of the described Ccdc50 exon
1 (data not shown). Although no other exons were found
toward the 5′ region of the gene, sequence analysis of the
5′-RACE-PCR products revealed the existence of a novel
exon between exons 3 and 4. This novel coding sequence,
exon 3b, comprises a 46-bp sequence located 243 bp
downstream of exon 3 in the genomic sequence (ﬁg. 2B).
A set of speciﬁc primers was therefore designed to amplify
overlapping fragments of the full-length Ccdc50 coding
sequence and to investigate the presence of putative novel
transcripts expressed in the inner ear containing thisnovel
exon (see the “Material and Methods” section, ﬁgs. 2A
and 3A, and table 1). This analysis led us to characterize
two additional transcripts (transcripts 3 and 4) that are
derived, respectively, from transcripts 1 and 2 by the in-
clusion of exon 3b. The presence of this exon in both
transcripts leads to a frameshift that generates a premature
stop codon at the beginning of exon 4. Transcripts in-
cluding exon 3b are predicted to generate a shorter protein
isoform of 95 aa. The last 15 aa of this isoform would
correspond to the predicted protein fragment encoded by
exon 3b. Similar to transcripts 1 and 2, the variants 3 and
4 were identiﬁed in the inner ear at all three stages tested
(ﬁg. 3A).
Although a BLAST analysis (BLASTN, TBLASTN, BLASTX,
or cross-species megaBLAST performed against theHuman
Genome Database) did not reveal the existence of this
exon in humans, a ClustalW alignment performed be-
tween the humanCCDC50 intron 3 and themouseCcdc50
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Figure 3. A, Panels showing the different RT-PCR ampliﬁcation products of the overlapping fragments used to identify the different
transcripts. Primer pairs and expected fragment sizes (in bp) are shown on the right. The ﬁrst panel (F1-R4) represents the primary
PCR, from which the remaining ones were obtained as nested PCRs. Each amplimer was conﬁrmed by direct sequencing. B, Restriction
pattern of the F7-R1 amplimer (nested PCR from F1-R4 containing the entire Ccdc50 ORF) digested with BseLI, showing the presence
of transcripts 1 and 2. Restriction pattern of transcript 1 (with exon 8) includes three bands of 522 bp, 445 bp, and 76 bp. Transcript
2 (without exon 8) digestion yields two bands of 922 bp and 76 bp. Exon 8 positive and negative controls were obtained by amplifying
cloned transcripts 1 and 2, respectively (see the “Material and Methods” section). C, Northern blot showing the expression pattern of
Ccdc50 in different mouse tissues. A probe against b-actin was used as a positive control. Lanes: 1, heart; 2, brain; 3, liver; 4, spleen;
5, kidney; 6, embryo; 7, lung; 8, thymus; 9, testes; and 10, ovary. MW p molecular-weight marker.
exon 3b sequences detected a stretch of human sequence
with ∼71% similarity to mouse exon 3b (ﬁg. 2D). Con-
served donor and acceptor splice sites, however, were not
present, suggesting that it is unlikely that there are human
splice variants containing the orthologous exon 3b. Fur-
ther studies at the RNA level are necessary for a more
deﬁnitive conclusion.
Although the mouse gene was not reported to contain
an exon homologous to human exon 6, cross-species
megaBLAST analysis, with the use of human exon 6 as a
query, revealed a putative mouse exon 6, and the con-
ceptual translation was ∼60% identical to the human pro-
tein (hmm192144). We therefore designed mouse exon 6–
speciﬁc primers (F10 and R14), and different RT-PCRswere
performed. This strategy allowed us to identify up to four
novel transcripts that include this exon (ﬁgs. 2A and 3A
and table 1). The presence of exon 6 in these transcripts
was conﬁrmed by direct sequencing of different overlap-
ping fragments (ﬁg. 2C). RT-PCR analysis of lung, brain,
and liver mRNA from a P58 mouse indicates that the ex-
pression of none of these transcripts, variants 1–8, is re-
stricted to the mouse inner ear.
Analysis of a northern blot withmRNA from10different
tissues (see the “Material and Methods” section) detected
two bands of ∼4.6 and 7.1 kb (ﬁg. 3C). These ﬁndings
indicated that the gene is ubiquitously expressed. The
band sizes do not correspond with the expected length
for mouse transcripts 1 and 2, reported to be ∼3.5 kb. They
are much longer and may correspond to transcripts with
alternate 3′ ends. Indeed, the 7.1-kb band is similar to the
predicted sizes of hmm192700 and hmm192422 (models
for transcripts 1 and 2, respectively), which contain a 3′
UTR of up to 6 kb.
A processed Ccdc50 pseudogene showing a 93% simi-
larity with mouse transcript 1 is present on mouse chro-
mosome 4 (GenBank accession number NG_005190.2).
The expression of the pseudogene has not been reported
so far, and it has a premature stop codon at exon 5. The
speciﬁc ampliﬁcation of Ccdc50 gene transcripts was en-
sured by designing RT-PCR primer pairs that take into ac-
count the sequence variations that exist with respect to
the pseudogene, and the PCR products were also veriﬁed
by direct sequencing.
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Figure 4. Western blot analysis and subcellular localization of the Ymer protein. A, Western blots of tissue samples from the GER,
stria vascularis (stria v.), and modiolus of the mouse cochlea. A prominent band of ∼38 kDa was revealed in the three tissues tested.
A minor higher-mass band of ∼88 kDa is also revealed and may correspond to a nonreducible dimeric form of the protein. B, Western
blot performed on proteins prepared by sequentially extracting whole cochlear tissue in TBS, 1 M NaCl (high salt [HS]), 10 mM Tris
(low salt [LS]), and 1% Triton X-100 (Tx-100). The residual remaining protein is the insoluble fraction. Ymer is detected only in the
TBS soluble fraction. C, Subcellular localization of mouse Ymer protein in transiently transfected NIH-3T3 cells. Cells transfected with
the mouse Ccdc50 transcript 1 show a cytoplasmic distribution of Ymer protein (red) that is absent from the nucleus (top left). Similar
results were obtained in Hela cells or when both types of cells were transfected with transcript 2 (data not shown). No staining was
obtained in cells transfected with the empty vector (mock [bottom left]). The transfection level was visualized by GFP expression (right,
top and bottom). D, NIH-3T3 cells transfected with the human mutated transcript 1 showed an aggregated perinuclear distribution of
the protein (arrow). Similar results were obtained in cells transfected with the mutated human transcript 2.
Ymer Is a Soluble Cytoplasmic Protein
A polyclonal antibody to Ymer was raised by injecting a
rabbit simultaneously with two peptides based on the pre-
dicted sequence of the mouse protein, one located in the
N-terminal half of the protein (residues 103–116) and the
other in the C-terminal region (residues 283–296) (see the
“Materials and Methods” section and ﬁg. 2A). The anti-
body was afﬁnity puriﬁed on a column to which both
peptides had been conjugated, and its speciﬁcity was as-
sessed by western blot analysis of protein extracts prepared
from three different tissues of the P2 mouse inner ear: the
greater epithelial ridge (GER), the stria vascularis, and the
modiolus. This analysis revealed a single prominent band
of ∼38 kDa in all three tissues. This molecular mass is
similar to that predicted from murine Ymer isoforms 1
and 2 (ﬁg. 4A). A minor band of approximately double
the mass was also detected and may correspond to a stable
dimeric form of the protein. These two bands were not
observed when blots were probed with nonimmune rabbit
IgGs at the same concentration (data not shown), indi-
cating the speciﬁcity of the puriﬁed antibody. On the basis
of the location of the two peptides used to generate the
polyclonal antibody, it should be possible to detect the
predicted isoforms 5 and 6 (ﬁg. 2A). They have not been
detected, however, which suggests they are expressed at
levels that escape the sensitivity of this technique.
The solubility of the Ymer protein was estimated by
immunoblotting proteins prepared by sequentially ex-
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tracting cochlear tissues with normal saline, buffers of
high and low ionic strength, and a buffer containing non-
ionic detergent (see the “Material and Methods” section).
The 38-kDa band was readily extracted in TBS (ﬁg. 4B).
The subcellular localization of Ymer was investigated in
NIH-3T3 and Hela cells transiently transfected with the
murine wild-type transcripts 1 and 2. Transfected cells
showed that Ymer is globally distributed in the cytoplasm
and is not present in the nucleus (ﬁg. 4C). Staining was
not observed in nondividing cells transfected with the
empty (mock) vector. Collectively, these results indicate
that Ymer is likely to be a soluble cytoplasmic protein.
To evaluate whether the identiﬁed mutation alters the
subcellular distribution of the protein, NIH-3T3 and Hela
cells were transiently transfected with mutated human
transcripts 1 and 2. Mutated protein is expressed but, un-
like the wild-type protein, is restricted to the perinuclear
area (ﬁg. 4D).
Expression Pattern of the Ymer Protein in the Mouse Inner
Ear
The spatiotemporal expression pattern of the Ymer pro-
tein was investigated in the developing and adult mouse
inner ear by immunohistochemistry with the afﬁnity-
puriﬁed antibody. We compared Ymer expression in the
mouse inner ear at embryonic stages E14.5 and E17.5 and
at several postnatal stages from P2 to P69.
At E14.5, strong punctate immunostainingwas detected
in the otic mesenchyme. Moreover, expression was de-
tected in the cells lining the lumen of the primitive coch-
lear duct and in the nerve ﬁbers of the spiral ganglion
(ﬁg. 5A). Immunolabeling of nerve ﬁbers invading the
cochlear epithelium was also observed at this stage. At
E17.5, a strong signal was detected only in the mesen-
chyme around the cochlear duct (ﬁg. 5B).
By P2, the mesenchymal staining became weaker, ex-
cept in the region of the spiral limbus, and Ymer expres-
sion was observed for the ﬁrst time in the apical region
of the developing pillar cells (PCs). Staining was also ob-
served in the cytoplasm of the outer hair cells (OHCs), in
their innervating nerve ﬁbers, and in the marginal cells
of the stria vascularis at this stage (ﬁg. 5C). At P9 and P12,
Ymer was detected strongly through the entire length of
the inner and outer PCs, and the staining in tissues of
mesenchymal origin was restricted to two major struc-
tures, the spiral limbus and the spiral ligament. Also at P9
and P12, labeling became more evident in the stria vas-
cularis (ﬁg. 5D and 5E). By P14 and P16, strong staining
was still evident in the PCs and in the marginal cells of
the stria vascularis. Staining was weak in the spiral limbus
and spiral ligament at this stage and had begun to appear
in Deiter’s cells (ﬁg. 5F and 5G). At P19 and P22, staining
was still intense in the PCs and stria vascularis and was
strong in the cell bodies and the processes of Deiter’s cells.
Weaker staining was observed in the spiral limbus and
spiral ligament at these stages (ﬁg. 5H and 5I). At P31,
when the inner ear is functionally mature, Ymer was ex-
pressed only in the stria vascularis and PCs (ﬁg. 5J). At
P69, the staining was still strong in PCs and less intense
in stria vascularis (ﬁg. 5K).
At all stages, for negative controls, we substituted the
primary antibody with nonimmune rabbit IgGs at the
same concentration or used preimmune sera from the rab-
bit used to generate the polyclonal antibody. Similar re-
sults were obtained in both controls, with nonspeciﬁc
staining only in one region of the cochlea corresponding
to the cells of the spiral ligament in the later stages of
development (ﬁg. 5L). These results indicate that the coch-
lear localization and expression levels of Ymer vary dy-
namically with time from embryonic stages onward (table
3).
The expression of Ymer in the vestibular maculae and
the cristae ampullaris was similar to that observed in the
cochlea (ﬁg. 6)—that is, with a strong signal observed in
the mesenchyme at the initial embryonic stages that pro-
gressively became weaker and was less prominent in the
adult (P33). Staining of the nerve ﬁbers innervating the
sensory epithelia was seen at E17.5 and P2 (ﬁg. 6A–6C).
Staining was initially detected in some cells of the vestib-
ular epithelium at E17.5 and became more evident at P2
(ﬁg. 6B–6D). Later, the staining increased and persisted to
adult stages in which it was mainly restricted to the apical
cytoplasm of the epithelial cells (ﬁg. 6E and 6F).
Ymer Colocalizes with Microtubules of the Cytoskeleton
and Mitotic Apparatus
The staining pattern of Ymer through the entire length
of PCs and Deiter’s cells suggested this protein could be
associated with their prominent microtubule-based cyto-
skeleton. This possibility was investigated by double im-
munolabeling for Ymer and different types of tubulins in
postnatal mouse inner ear sections. This analysis showed
that Ymer exhibits overlap with the microtubule bundles
of PCs and Deiter’s cells and with the complex microtu-
bule structure in the interdigitating processes of the mar-
ginal and intermediate cells in the stria vascularis (ﬁg. 7A
and 7C). Moreover, a clear colocalization was observed in
the apical cytoplasm of vestibular epithelial cells (ﬁg. 7B).
The subcellular localization of Ymer was similarly inves-
tigated in the mouse NIH-3T3 cell line. Double labeling
of nontransfected cells revealed that Ymer colocalized
with microtubules of the mitotic apparatus of cells un-
dergoing division. During the nuclear division, or kary-
okinesis, Ymer colocalizes with microtubules of the mi-
totic spindle. In the ﬁnal steps of cell division, during
cytokinesis, Ymer overlaps with the midzone, a region of
bundled microtubules between the migrated chromo-
somes, and then with the microtubulemidbody contained
in the intercellular bridge that is created as the cleavage
furrow ingresses and compresses the midzone (ﬁg. 7D).
Taken together, these results suggest that Ymer is associ-
ated with microtubule-based structures.
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Figure 5. Spatiotemporal expression pattern of Ymer protein in the mouse cochlea. Immunohistochemistry was performed on mouse
inner ear sections at embryonic stages E14.5 and E17.5 and several postnatal stages from P2 to P69. Inset in panel C shows a magniﬁcation
of the apical region of developing PCs and the OHCs. Panel L shows a negative control performed on a P69 section with the use of
nonimmune rabbit IgG. Similar results were obtained when we used preimmune sera from the rabbit used to generate the polyclonal
antibody. Mp mesenchyme; CDp cochlear duct; NFp nerve ﬁbers; SLip spiral limbus; SVp stria vascularis; SLgp spiral ligament;
DC p Deiter’s cells. Scale bar p 100 mm.
Discussion
The results of this study indicate that a mutation in
CCDC50, a gene encoding a tyrosine phosphorylated ef-
fector of EGF-mediated cell signaling known as “Ymer,”
causes nonsyndromic, postlingual, progressive sensori-
neural DFNA44 hearing loss in the Spanish family. A thor-
ough investigation of the protein expression pattern in
the mouse inner ear reveals that a spatiotemporal corre-
lation can be established between the distribution of Ymer
and the tubulin cytoskeleton during the development and
postnatal maturation of different cell types in the organ
of Corti.14,15 At E14.5, Ymer was detected in the nerve
ﬁbers of the spiral ganglion. Tubulin is one of the major
components of the cells of the spiral ganglion and their
axonal projections during development.14 In OHCs, Ymer
is detected at P2 as cells elaborate their microtubule cy-
toskeleton and begin to express speciﬁc properties as mo-
tor cells.14–17 Ymer is initially present in the apex of PCs
at ∼P0, at a time and place where the nucleation of mi-
crotubules begins,18 and then throughout the whole PC
body as the cells acquire their adult morphology and the
microtubule scaffold projects toward the basal membrane
to eventually span the entire length of the cell.19 In Dei-
ter’s cells, which mature after PCs,14,16 Ymer is clearly ob-
served at P19. Interestingly, colocalization studies show
spatial overlap between Ymer and the microtubule cyto-
skeleton in PCs and Deiter’s cells, and the staining pattern
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Figure 6. Spatiotemporal expression pattern of Ymer protein in
the mouse vestibular system. Ymer staining was investigated on
vestibular sections from embryonic (A and B, E17.5), neonatal (C
and D, P2) and adult (E, P16 and F, P33) stages. Panels A, C, and
E show cristae ampullaris; panels B, D, and F show maculae (B and
F, utricles; D, saccule). Insets in panels B, E, and F show mag-
niﬁcations of the corresponding sensory epithelia. NF p nerve
ﬁbers. Scale bars p 50 mm.
Table 3. Expression Level of Ymer Protein in Different Mouse Cochlear Structures at Different Stages of Development
Structure
Stage
E14.5 E17.5 P2 P9 P12 P14 P16 P19 P22 P31 P69
Mesenchyme and derived structures           
Nerve ﬁbers           
OHCs           
PCs           
Deiter’s cells           
Stria vascularis           
is compatible with the structure of the compact sheaths
seen in these cell types.20,21 In the stria vascularis, which
starts its maturation after birth,22 Ymer is ﬁrst detected at
P2. It is known that a complex rearrangement of micro-
tubules occurs during maturation of marginal and inter-
mediate cells of the mouse stria vascularis.23,24 Interest-
ingly, in the adult stria, a clear colocalization of Ymer is
seen with the microtubule-based cytoskeleton. Of note,
although Ymer is dynamically expressed during inner ear
development, its expression in the adult cochlea appears
to be restricted to the PCs and the stria vascularis. A simi-
lar correlation is observed during the maturation of the
vestibular system. At E17.5, the expression of Ymer is
observed in the nerve ﬁbers of the vestibular sensory
epithelium, and, in the adult, it colocalizes with the mi-
crotubule-based cytoskeleton that is prominent in the
apical cytoplasm of vestibular hair cells.25 Notably, Ymer
colocalizes with microtubules of the mitotic apparatus in
cells undergoing division (ﬁg. 7D), suggesting it is also
functioning in processes that involve the dynamic rear-
rangement of microtubules. However, the existence of
the breast cancer cell line MCF7, in which Ymer is not
expressed,11,26 suggests that Ymer is not involved in the
crucial steps of mitosis.
Collectively, these ﬁndings strongly suggest that Ymer
is associated with microtubule-based structures and that
it may play roles in the developing and adult inner ear.
It can therefore be suggested that the pathogenesis of
DFNA44 hearing loss, a postlingual, progressive form of
deafness, results from the destabilization of the cytoske-
leton in the PCs and stria vascularis of the adult cochlea.
PCs are supporting cells with a highly developed cyto-
skeleton composed of microﬁlaments and microtubules,
which undergoes a mechanical stress in response to the
sound stimuli. Moreover, the distribution and orientation
of microtubules in marginal and intermediate cells is cru-
cial to maintain the architecture of the stria vascularis,23,
27 and it has been suggested that the depolymerization of
microtubules in marginal cells of the adult mouse may
underlie strial atrophy.24 Thus, a failure in the integrity of
the cytoskeleton over time may explain the progressive
hearing loss. Finally, the fact that Ymer is expressed at
similar levels in PCs and stria vascularis in the basal and
apical turns (data not shown) may explain why all fre-
quencies are affected in the patients. Interestingly, al-
though CCDC50 is ubiquitously expressed, the hearing
loss in this family is not accompanied by alterations in
other organs. Several examples exist of genes with wide-
spread expression patterns and a role in inner ear devel-
opment that, once mutated, cause a hearing loss with clin-
ical features similar to those observed in our family with
DFNA44 hearing loss. This is the case for EYA4, a gene
encoding a transcriptional activator that is involved in
DFNA10 (MIM 601316) hearing impairment,28 and for
TFCP2L3, a gene encoding a transcription factor respon-
sible for DFNA28 (MIM 608641) hearing loss.29 The exis-
tence of redundancy is one of the possible mechanisms
Figure 7. Colocalization studies of Ymer and different tubulins in inner ear sections and NIH-3T3 cells. A, In the mature cochlea
(P22), Ymer colocalizes with (b1b2) tubulin in the cytoskeleton of PCs and Deiter’s cells (DC). Similar results were obtained for a-
tubulin and for both acetylated and polyglutamylated tubulin (data not shown). B, In the utricule of a P14 mouse, Ymer shows spatial
overlap with the cytoskeleton of microtubules in the apical cytoplasm of the epithelial cells (EC). C, In adult stria vascularis (P31),
Ymer colocalizes with the microtubule-based cytoskeleton of marginal and intermediate cells. In panels B and C, no colocalization is
seen with the actin cytoskeleton (phalloidin panel). D, Ymer colocalizes with microtubules of the mitotic apparatus in nontransfected
NIH-3T3 cells that are undergoing cell division. In metaphase (top panels), Ymer distribution overlaps with microtubules of the mitotic
spindle (MS). During early telophase (middle panels), Ymer colocalizes with the midzone (MZ), a region of bundled microtubules between
the migrated chromosomes. In late telophase (lower panels), as the cleavage furrow ingresses compressing the midzone, Ymer colocalizes
with the microtubule midbody (MB) contained in the intercellular bridge.
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that may explain the nonsyndromic nature of these
phenotypes.
Several studies have demonstrated that EGF30–33 and
platelet-derived growth factor (PDGF)34,35 are required for
the development and differentiation of the inner ear. The
cellular response to these growth factors is mediated by
their corresponding receptors, EGFR and PDGFR, and by
the phosphorylation of a large number of intracellular ef-
fector molecules.36–38 Currently, little is known about the
precise role that Ymer plays in the EGF-mediated signaling
pathway. It has been reported that human Ymer under-
goes tyrosine phosphorylation and ubiquitination in re-
sponse to EGF stimulation and that it may be an inhibitor
of EGFR downregulation.9–11 In this process, the modiﬁed
shorter isoform binds to the ubiquitinated EGFR through
residues that involve the phosphorylation sites and MIU
domains.11 The longer isoform (with exon 6) does not,
however, bind to the EGFR and has no effect on its down-
regulation.11 As for the longer human isoform, the pre-
dicted mouse isoform 2, which lacks several residues
shared by both MIU domains as a consequence of exon 8
skipping, may not be involved in EGFR regulation. In ad-
dition, mouse transcripts 3, 4, 7, and 8 are predicted to
generate a shorter isoform of 95 aa that would lack all the
described EGFR binding domains and the motifs for post-
translational modiﬁcations. Interestingly, a recombinant
shorter isoform of human Ymer that lacks the C-terminal
portion in which the DFNA44 mutation was found still
retains the ability to interact with EGFR,11 thus suggesting
that the mutation identiﬁed in this work might not be
affecting Ymer’s role on EGFR regulation. Transfection ex-
periments performed with the mutated human isoforms
1 and 2 show, however, that the mutant protein is mis-
localized and accumulates in the perinuclear area, sug-
gesting that the mutation identiﬁed in the family with
DFNA44 hearing loss might cause a loss of function of the
Ymer protein. Further investigation is required to isolate
the distinct roles that Ymer isoforms are predicted to play.
In summary, the results obtained in this work provide
interesting clues that may improve our understanding of
the role for Ymer, particularly in hearing and deafness.
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